cagrilintide novo Nordisk flags promise in hunt for next obesity drug Novo Nordisk's stock drops despite
Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Data on Novo Nordisk experimental weight loss drug show mostly mild side effects Reuters Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment Weight loss: New drug CagriSema leads to 14% weight loss in trial
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


:max_bytes(150000):strip_icc()/GettyImages-2197227432-6dabff12e088403c8032fbae8a53811d.jpg)